Pipeline — registered trials by phase
No registered trials in this stage.
No registered trials in this stage.
A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
— · Graves' Disease · Recruiting · est. 2028-06
A Proof-of-Concept Study to Assess Batoclimab in Participants With Graves' Disease
— · Graves Disease · Completed · est. 2025-07-25
Study of RVT-1401 for the Treatment of Patients With Moderate to Severe Active Graves' Ophthalmopathy (GO)
— · Graves' Ophthalmopathy · Completed · est. 2020-02-29
A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
— · Graves' Disease · Recruiting · est. 2027-05
Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
— · Chronic Inflammatory Demyelinating Polyneuropathy · Recruiting · est. 2028-08
A Study of RVT-1401 in Myasthenia Gravis (MG) Patients
— · Myasthenia Gravis · Completed · est. 2020-10-07
A Long-Term Extension Study of IMVT-1402 in Adult Participants With Graves' Disease (GD)
— · Graves' Disease · Enrolling By Invitation · est. 2030-03
A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE)
— · Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus · Active Not Recruiting · est. 2026-10
Efficacy and Safety of IMVT-1402 in Adult Participants With Primary Sjogren's Disease With Moderate to Severe Systemic Disease Activity
— · Primary Sjögren's Syndrome · Active Not Recruiting · est. 2028-07
A Study to Evaluate the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Active, Difficult to Treat Rheumatoid Arthritis
— · Rheumatoid Arthritis · Active Not Recruiting · est. 2027-09
Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease
— · Thyroid Eye Disease · Completed · est. 2025-11-02
Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
— · Generalized Myasthenia Gravis · Recruiting · est. 2027-12
Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease
— · Thyroid Eye Disease · Completed · est. 2026-02-03
No approved products listed under this sponsor in Drugs@FDA (partnered or subsidiary products may be listed elsewhere).
Source: ClinicalTrials.gov (trials where Immunovant is lead sponsor; 13 active or completed) and Drugs@FDA (0 approved products). Registry data can include older or partnered programs; the company's own pipeline page is the official list.
SEC filings — insider trading forms excluded
- 8-K2026-09-03Current report (material event)
- SCHEDULE 13G/A2026-08-14SCHEDULE 13G/A
- 10-Q2026-08-06Quarterly report
- 8-K2026-08-06Current report (material event)
- ARS2026-07-22Annual report to holders
- DEFA14A2026-07-22DEFA14A
- DEF 14A2026-07-22Proxy statement
- 10-K2026-05-20Annual report
- 8-K2026-05-20Current report (material event)
- 10-Q2026-02-06Quarterly report
- 8-K2026-02-06Current report (material event)
- SCHEDULE 13D/A2025-12-12SCHEDULE 13D/A
- 8-K2025-12-12Current report (material event)
- 424B52025-12-12Prospectus (offering)
- 8-K2025-12-11Current report (material event)
- FWP2025-12-11FWP
- 8-K2025-11-21Current report (material event)
- 10-Q2025-11-10Quarterly report
- 8-K2025-11-10Current report (material event)
- SCHEDULE 13G/A2025-11-05SCHEDULE 13G/A
- 8-K2025-09-03Current report (material event)
- 8-K2025-08-28Current report (material event)
- 10-Q2025-08-11Quarterly report
- 8-K2025-08-11Current report (material event)
- 8-K2025-07-29Current report (material event)
- ARS2025-07-09Annual report to holders
- DEFA14A2025-07-09DEFA14A
- DEF 14A2025-07-09Proxy statement
- 10-K2025-05-29Annual report
- 8-K2025-05-29Current report (material event)
- S-82025-04-30Employee stock plan
- SCHEDULE 13D/A2025-04-21SCHEDULE 13D/A
- 8-K2025-04-21Current report (material event)
- SCHEDULE 13G2025-03-26SCHEDULE 13G
- 8-K2025-03-19Current report (material event)
- SCHEDULE 13G/A2025-03-07SCHEDULE 13G/A
- 10-Q2025-02-06Quarterly report
- 8-K2025-02-06Current report (material event)
- 8-K2025-01-24Current report (material event)
- 424B32025-01-24424B3
Source: SEC EDGAR. Forms 3/4/5 and 144 (insider transactions) are intentionally left out.